Dr. Reddy's Laboratories has launched blood cancer drug Invista in India. The company's product is a formulation of Dasatinib that is bioequivalent to the innovator brand, Dr Reddy's Laboratories. Invista, which is available in strengths of 50, 70 and 100 mg tablets, is indicated for the treatment of primarily Chronic Myeloid Leukemia (CML). CML is a type of blood-cell cancer that begins in the bone marrow.
The development and launch of Invista is a significant step forward in improving access to medicines at an affordable price for CML patients in India.
Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.
